Panoptica, Inc.

Alcon Research, Ltd.

Arrowhead Pharmaceuticals, Inc.

Arrowhead Research Corporation

Other

Alcon, Inc.

Martin B Wax

David P Bingaman

Abbot F Clark

Jon E Chatterton

Paul G Chaney

Adrian M Timmers

Masood A Chowhan

Bahram Asgharian

Allan R Shepard

The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.

Ocular formulations for drug-delivery to the posterior segment of the eye

The present application relates to topical formulations comprising Compound-I or its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.

Ocular formulations for drug-delivery and protection of the anterior segment of the eye

RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.

RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions

RNA interference is provided for inhibition of tumor necrosis factor &#x3b1; (TNF&#x3b1;) by silencing TNF&#x3b1; cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF&#x3b1; converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF&#x3b1; targets, in particular, is useful for treating patients having a TNF&#x3b1;-related condition or at risk of developing a TNF&#x3b1;-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.

RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis

RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesis

RNA interference is provided for inhibition of tumor necrosis factor &#x3b1; (TNF&#x3b1;) by silencing TNF&#x3b1; cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF&#x3b1; converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF&#x3b1; targets, in particular, is useful for treating patients having a TNF&#x3b1;-related condition or at risk of developing a TNF&#x3b1;-related condition such as the ocular conditions associated with elevated intraocular pressure (IOP), including glaucoma and ocular hypertension.

RNAi-related inhibition of TNF&#x3b1; signaling pathway for treatment of glaucoma

RNAi-related inhibition of TNF&#x3b1; signaling pathway for treatment of ocular angiogenesis

Disclosed is a pharmaceutical composition comprising (a) a bioerodible water insoluble polymer matrix comprising a polyester polymer, wherein the polymer matrix has a melting point of less than 60&#xb0; C. and (b) an active agent dispersed within the polymer matrix, wherein the composition is formulated to controllably release the active agent for a pre -determined period of time to a target site. Also disclosed are methods of treating a disease or condition with the disclosed compositions.

Water insoluble polymer matrix for drug delivery

RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; &#x3b2;1- and &#x3b2;2 adrenergic receptors; acetylcholinesterase; Na/K-ATPase; and Na&#x2014;K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.

Growing community of inventors

Westlake, TX, United States of America

Martin B Wax